Evan Lyerly

Affiliations reported with papers

• Laboratory of Novel Biologics, Medical Microbiology and Immunology, University of California, Davis, Davis, CA 95616, USA; Undergraduate Research Program Volunteers, University of Virginia, Charlottesville VA; Blavatnik Institute, Harvard Medical School, Boston MA.2021 publication record
• Laboratory of Novel Biologics, University of Virginia, Charlottesville, VA, USA.2021 publication record
• Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA.2021 publication record
• Undergraduate Research Program, University of Virginia, Charlottesville, VA, USA.2021 publication record
• Laboratory of Novel Biologics, University of Virginia School of Medicine; Department of Biochemistry and Molecular Genetics, UVA Cancer Center, University of Virginia School of Medicine.2020 publication record

Linked publications

A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors 2021

Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies 2021

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody 2020

Related research

DR5 agonism and PD-L1 immune evasion

Surface charge and DR5 antibody response